Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by gudisgoodon Mar 22, 2023 3:32pm
131 Views
Post# 35354455

RE:RE:Love the markets like this ...

RE:RE:Love the markets like this ...Re: operations... in the first nine months of 2022, we had $48M of operational cash flow before working capital adjustments. If you exclude the $6M settlement, that's $42M of operational cash flow in nine months. (Working capital should have reached its "normal" level at the end of 2022.)

There will still be increases in working capital in Q4/22 though. But we may be at around $50M of operational cash flow before working capital adjustments for 2022. At least I hope so. With any meaningful growth in 2023, the operations will already be generating plenty of cash relative to the valuation, in my opinion.

On top of that, we have a very strong balance sheet, and that's a significant factor. Around $280M of net cash, marketable securities and financial instruments (in Q3/22). That's a very different position compared to the companies levered up to the hilt.

With that (and, again, operations that generate plenty of additional cash), we should be well-positioned to take an advantage of any opportunities out there. Hopefully we'll find them sooner rather than later. :)
<< Previous
Bullboard Posts
Next >>